Rectiv

Treatment for Anal Fissure and Fistula

Update: Rectiv (nitroglycerin ointment) Now FDA Approved - June 21, 2011

Cellegy Reports Status of Response Date for FDA Review

BRISBANE, Calif., June 30, 2005 -- Cellegy Pharmaceuticals, Inc. announced that it has been informed by the U.S. Food and Drug Administration that the FDA is still reviewing the Company's recently submitted amended New Drug Application (NDA) for Cellegesic (0.4% nitroglycerin ointment), for the treatment of pain associated with chronic anal fissure. The Company expects the agency to respond soon after its review is completed.

About Cellegy
Cellegy Pharmaceuticals is a specialty biopharmaceutical company that develops and commercializes prescription drugs for the treatment of women's health care conditions, including reduction in the transmission of HIV and sexual dysfunction, gastrointestinal disorders and certain cancers.




Posted: June 2005

Related Articles

Rectiv (nitroglycerin) FDA Approval History

View comments

Hide
(web2)